Cargando…
Severe Hemolysis in a COVID-19 Patient with Paroxysmal Nocturnal Hemoglobinuria
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), has been demonstrated to be able to activate complement, making patients with deficiency in negative complement regulation, such as paroxysmal nocturnal hemoglobinuria (PNH), part...
Autores principales: | Otieno, Steve Biko, Altahan, Alaa, Kaweeta, Fnu, Karri, Saradasri, Alnoor, Fnu, Johnson, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285198/ https://www.ncbi.nlm.nih.gov/pubmed/34306774 http://dx.doi.org/10.1155/2021/6619177 |
Ejemplares similares
-
COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria
por: Gerber, Gloria F., et al.
Publicado: (2021) -
Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: is eculizumab indicated?
por: Bellido, M., et al.
Publicado: (2012) -
The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria
por: Lazana, Ioanna, et al.
Publicado: (2023) -
Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond Siu Ming, et al.
Publicado: (2023) -
Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond S. M., et al.
Publicado: (2022)